Maria-Victoria Mateos

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

F. Ghilotti, A. Perrot, S. Manier, 2023, Advances in therapy.

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.

M. Boccadoro, A. Symeonidis, E. Katodritou, 2023, The Lancet. Haematology.

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

A. Oriol, B. Paiva, J. San-Miguel, 2024, Haematologica.

Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study

A. Larocca, F. Schjesvold, H. Abdulhaq, 2023, European journal of haematology.

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy : analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010 .

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study

A. Nooka, R. Verona, N. V. D. van de Donk, 2023, Cancer.